BridgeMD
Mannitol versus normal saline in brain death donors and recipients of kidney allograft on delayed graft function (MAVERICK)
EU CTIS ID: 2024-518817-24-01
What this study is testing
To define if mannitol can be used to improve the results of kidney transplantation by reducing delayed graft function.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients receiving a kidney allograft from adult brain-dead donor.
You likely can't join if
- Recipient or donor age under 18 years.
- No informed consent from kidney recipient.
- Mannitol allergy
- Pre-emptive kidney transplantation - patient has not yet been to dialysis
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.